Physician profile
Jack D Denver
NPI 1154361343
$1,131.38
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $642 · 2021: $15.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $473.81 | 2019-2020 | |
| Forte Bio-Pharma LLC | $146.22 | 2020 | |
| Assertio Therapeutics, INC. | $134.67 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $99.13 | 2020-2021 | |
| Amgen INC. | $67.57 | 2019 | |
| Sentynl Therapeutics, INC. | $58.49 | 2019 | |
| Collegium Pharmaceutical, INC. | $41.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.15 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $17.53 | 2019 | |
| Lilly USA, LLC | $15.52 | 2020 | |
| Upsher-Smith Laboratories LLC | $13.66 | 2019 | |
| Daiichi Sankyo INC. | $13.11 | 2019 | |
| Tactile Systems Technology INC | $12.81 | 2019 | |
| Currax Pharmaceuticals LLC | $12.40 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Denver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.